Autopsy report · NCT03747419
Avelumab and Radiation in Muscle-Invasive Bladder Cancer
Cause of deathSlow enrollment
“In agreement with the drug sponsor and the institution, the trial has been terminated due to slow accrual.”
Life of this trial
- Ran for about 6 years 2 months before it stopped.
- 14 participants enrolled.
- Results were posted on the registry 8 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Dana-Farber Cancer Institute
- Sponsor type
- University, hospital or other
- Conditions
- Bladder Cancer; Muscle Invasive Bladder Cancer
- Interventions
- Avelumab; Radiation
- Participants
- 14
- Sites
- 2
- Countries
- United States
Trials that died the same way
- Pancreatic Enzyme Supplementation for Celiac Disease
“The trial was terminated prematurely by the sponsor for administrative reasons.” - Estradiol Therapy In Transgender Women to Research Interactions With HIV Therapy
“Trial terminated by Sponsor.” - TAS-117 in Patients With Advanced Solid Tumors Harboring Germline PTEN Mutations
“The Sponsor had decided to terminate this clinical trial due to an insufficient rate of accrual of patients.” - Study to Determine the Safety and Efficacy of INCB018424 in Patients With Polycythemia Vera or Essential Thrombocythemia
“Termination of the clinical trial by sponsor.” - A Study of the Safety and Pharmacokinetics of AGS-8M4 Given in Combination With Chemotherapy in Women With Ovarian Cancer
“Trial was terminated to allow sponsors to evaluate the future development of the drug program”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.